2021-08-12| Asia-Pacific

Korea’s Celltrion Pushes for Broader Use of COVID-19 Treatment both Domestically And Abroad

by Kathy Huang
Share To

South Korean pharma giant Celltrion has made a lot of breakthroughs on its COVID-19 treatment recently. On August 10th, the company said it had received approval from Australia’s Therapeutic Good Administration (TGA) for the clinical trial of its inhalable form of COVID-19 treatment, Regkirona, CT-P59.

Also, the application for the Phase 3 trial of Regkirona in Korea is under review by Korea’s Ministry of Food and Drug Safety. Regkirona was approved by the agency in December 2020. This intravenous antibody treatment is currently used to treat severe patients. In the Phase 3 trial, Celltrion will verify its safety and efficacy in a wider range of patients with mild COVID-19 over 12 years of age.


Clinical Trial of Inhaled Regkirona Approved by Australian Government

The inhaled form of Regkirona is developed under the collaboration between Celltrion and North California-based Inhalon Biopharma. Since last July, the two companies have embarked on the development and have finished the animal studies of inhaled Regkirona this January.

The Phase 1 clinical trial in Australia will involve 24 healthy people, and the next phase of the trial will be launched later this year, to verify the efficacy of the treatment. 


Approval Status Among Other Countries

Regkirona has just won Emergency Use Authorization by the Brazilian health regulator, allowing its use on hospitalized patients. Earlier in July, it also received Emergency Use Authorization from the Indonesian government.

The drug is currently under rolling review by the European Medicines Agency. In addition, Celltrion plans to apply for Emergency Use Authorization from the USFDA as well.

© All rights reserved. Collaborate with us:
Related Post
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
Celltrion and WuXi XDC Partner to Advance ADC Development and Manufacturing
GeneOnline’s Weekly News Highlights: Oct 22-Oct 27
Company Presentations at BIO 2024 Inspire Partnering
GV Regains Compliance with Nasdaq Minimum Bid Price Requirement
ARPA-H Fast-Tracks Biotech Startups: Funding Insights from BIO 2024 Panel
Gene Therapy Innovations and Financial Challenges for the Future of Medicine
BIO Releases DEI Survey in Partnership with Korn Ferry
Advancing Healthcare Accessibility and Sustainable Development
New CRISPR Method Enables Gene Edits in Cockroaches and All Insects
Scroll to Top